Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer

We performed a meta-analysis to comprehensively investigate the efficacy and safety of immune-checkpoint inhibitors (ICIs) plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The primary outcome was overall survival (OS). The secondary outcomes included progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fei, Zhao, Wencheng, Gong, Xiaomei, Ren, Shengxiang, Su, Chunxia, Jiang, Tao, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477983/
https://www.ncbi.nlm.nih.gov/pubmed/32900864
http://dx.doi.org/10.1136/jitc-2020-001300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477983/
https://www.ncbi.nlm.nih.gov/pubmed/32900864
http://dx.doi.org/10.1136/jitc-2020-001300

Ejemplares similares